Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center

Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum. Long-term therapy is generally required to achieve and maintain disease control.1 In May 2021 the US Food and Drug Administration approved the use of ozanimod in patients with moderate to severe UC. We descri...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical gastroenterology and hepatology 2023-08, Vol.21 (9), p.2407-2409.e2
Hauptverfasser:	Cohen, Nathaniel A., Choi, David, Choden, Tenzin, Cleveland, Noa Krugliak, Cohen, Russell D., Rubin, David T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Colitis, Ulcerative - drug therapy Humans Indans - therapeutic use Oxadiazoles - therapeutic use United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	2409.e2
container_issue	9
container_start_page	2407
container_title	Clinical gastroenterology and hepatology
container_volume	21
creator	Cohen, Nathaniel A. Choi, David Choden, Tenzin Cleveland, Noa Krugliak Cohen, Russell D. Rubin, David T.
description	Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum. Long-term therapy is generally required to achieve and maintain disease control.1 In May 2021 the US Food and Drug Administration approved the use of ozanimod in patients with moderate to severe UC. We describe the first report of the use of ozanimod in real-world clinical practice.
doi_str_mv	10.1016/j.cgh.2022.03.035
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2647654010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S154235652200310X</els_id><sourcerecordid>2647654010</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-3490a02a6a9891541a96070e4c48e1ef4abda6facb6b708a529d719d4eea91bd3</originalsourceid><addsrcrecordid>eNp9kE1rGzEQhkVJqNOkP6CXomMu60q70u6qORW3-QCDIdj0KGal2URmd-VKciD59ZWx02NhYHR45uHVS8gXzuac8frbdm6enuclK8s5q_LID-SCS1EWTcPF2eldyVrOyKcYt4yVSqjmI5lVsmp51coLgqs3mNzoLXUTTc9I1wEhjTgl6nu6GQwGSO4F6cIPLrn4nT5MecNAHxGG4rcPg6U_IQG9DX6kQJcQnrIFQ4bCK11kE4Yrct7DEPHzaV-Sze2v9eK-WK7uHhY_loXJiVJRCcWAlVCDalUOz0HVrGEojGiRYy-gs1D3YLq6a1gLslS24coKRFC8s9UluT56d8H_2WNMenTR4DDAhH4fdVmLppaCcZZRfkRN8DEG7PUuuDFH1pzpQ7t6q3O7-tCuZlUemW--nvT7bkT77-K9zgzcHAHMn3xxGHQ0DieD1gU0SVvv_qP_C_xxig8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2647654010</pqid></control><display><type>article</type><title>Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cohen, Nathaniel A. ; Choi, David ; Choden, Tenzin ; Cleveland, Noa Krugliak ; Cohen, Russell D. ; Rubin, David T.</creator><creatorcontrib>Cohen, Nathaniel A. ; Choi, David ; Choden, Tenzin ; Cleveland, Noa Krugliak ; Cohen, Russell D. ; Rubin, David T.</creatorcontrib><description>Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum. Long-term therapy is generally required to achieve and maintain disease control.1 In May 2021 the US Food and Drug Administration approved the use of ozanimod in patients with moderate to severe UC. We describe the first report of the use of ozanimod in real-world clinical practice.</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2022.03.035</identifier><identifier>PMID: 35381385</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Colitis, Ulcerative - drug therapy ; Humans ; Indans - therapeutic use ; Oxadiazoles - therapeutic use ; United States</subject><ispartof>Clinical gastroenterology and hepatology, 2023-08, Vol.21 (9), p.2407-2409.e2</ispartof><rights>2023 AGA Institute</rights><rights>Copyright © 2023 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-3490a02a6a9891541a96070e4c48e1ef4abda6facb6b708a529d719d4eea91bd3</citedby><cites>FETCH-LOGICAL-c353t-3490a02a6a9891541a96070e4c48e1ef4abda6facb6b708a529d719d4eea91bd3</cites><orcidid>0000-0001-5647-1723</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S154235652200310X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35381385$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cohen, Nathaniel A.</creatorcontrib><creatorcontrib>Choi, David</creatorcontrib><creatorcontrib>Choden, Tenzin</creatorcontrib><creatorcontrib>Cleveland, Noa Krugliak</creatorcontrib><creatorcontrib>Cohen, Russell D.</creatorcontrib><creatorcontrib>Rubin, David T.</creatorcontrib><title>Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum. Long-term therapy is generally required to achieve and maintain disease control.1 In May 2021 the US Food and Drug Administration approved the use of ozanimod in patients with moderate to severe UC. We describe the first report of the use of ozanimod in real-world clinical practice.</description><subject>Colitis, Ulcerative - drug therapy</subject><subject>Humans</subject><subject>Indans - therapeutic use</subject><subject>Oxadiazoles - therapeutic use</subject><subject>United States</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rGzEQhkVJqNOkP6CXomMu60q70u6qORW3-QCDIdj0KGal2URmd-VKciD59ZWx02NhYHR45uHVS8gXzuac8frbdm6enuclK8s5q_LID-SCS1EWTcPF2eldyVrOyKcYt4yVSqjmI5lVsmp51coLgqs3mNzoLXUTTc9I1wEhjTgl6nu6GQwGSO4F6cIPLrn4nT5MecNAHxGG4rcPg6U_IQG9DX6kQJcQnrIFQ4bCK11kE4Yrct7DEPHzaV-Sze2v9eK-WK7uHhY_loXJiVJRCcWAlVCDalUOz0HVrGEojGiRYy-gs1D3YLq6a1gLslS24coKRFC8s9UluT56d8H_2WNMenTR4DDAhH4fdVmLppaCcZZRfkRN8DEG7PUuuDFH1pzpQ7t6q3O7-tCuZlUemW--nvT7bkT77-K9zgzcHAHMn3xxGHQ0DieD1gU0SVvv_qP_C_xxig8</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Cohen, Nathaniel A.</creator><creator>Choi, David</creator><creator>Choden, Tenzin</creator><creator>Cleveland, Noa Krugliak</creator><creator>Cohen, Russell D.</creator><creator>Rubin, David T.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5647-1723</orcidid></search><sort><creationdate>202308</creationdate><title>Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center</title><author>Cohen, Nathaniel A. ; Choi, David ; Choden, Tenzin ; Cleveland, Noa Krugliak ; Cohen, Russell D. ; Rubin, David T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-3490a02a6a9891541a96070e4c48e1ef4abda6facb6b708a529d719d4eea91bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Colitis, Ulcerative - drug therapy</topic><topic>Humans</topic><topic>Indans - therapeutic use</topic><topic>Oxadiazoles - therapeutic use</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cohen, Nathaniel A.</creatorcontrib><creatorcontrib>Choi, David</creatorcontrib><creatorcontrib>Choden, Tenzin</creatorcontrib><creatorcontrib>Cleveland, Noa Krugliak</creatorcontrib><creatorcontrib>Cohen, Russell D.</creatorcontrib><creatorcontrib>Rubin, David T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cohen, Nathaniel A.</au><au>Choi, David</au><au>Choden, Tenzin</au><au>Cleveland, Noa Krugliak</au><au>Cohen, Russell D.</au><au>Rubin, David T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2023-08</date><risdate>2023</risdate><volume>21</volume><issue>9</issue><spage>2407</spage><epage>2409.e2</epage><pages>2407-2409.e2</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum. Long-term therapy is generally required to achieve and maintain disease control.1 In May 2021 the US Food and Drug Administration approved the use of ozanimod in patients with moderate to severe UC. We describe the first report of the use of ozanimod in real-world clinical practice.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35381385</pmid><doi>10.1016/j.cgh.2022.03.035</doi><orcidid>https://orcid.org/0000-0001-5647-1723</orcidid></addata></record>
fulltext	fulltext
identifier	ISSN: 1542-3565
ispartof	Clinical gastroenterology and hepatology, 2023-08, Vol.21 (9), p.2407-2409.e2
issn	1542-3565 1542-7714
language	eng
recordid	cdi_proquest_miscellaneous_2647654010
source	MEDLINE; Elsevier ScienceDirect Journals
subjects	Colitis, Ulcerative - drug therapy Humans Indans - therapeutic use Oxadiazoles - therapeutic use United States
title	Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A28%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ozanimod%20in%20the%20Treatment%20of%20Ulcerative%20Colitis:%20Initial%20Real-World%20Data%20From%20a%20Large%20Tertiary%20Center&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Cohen,%20Nathaniel%20A.&rft.date=2023-08&rft.volume=21&rft.issue=9&rft.spage=2407&rft.epage=2409.e2&rft.pages=2407-2409.e2&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2022.03.035&rft_dat=%3Cproquest_cross%3E2647654010%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2647654010&rft_id=info:pmid/35381385&rft_els_id=S154235652200310X&rfr_iscdi=true